Fig. 3: Validation of prognostic ability of TCMF2-score.
From: Prognostic value of nuclear features based on tumor-associated collagen signatures in breast cancer
a Distribution of TCMF2-score in the training cohort. b The scatter plot of the patient disease-free survival overview in the training cohort. c The heatmap showed the relationship between the TCMF2-score and DFS in three cohorts. d Distribution of DFS in the low- and high-risk groups in three cohorts. e Kaplan–Meier survival analysis based on TCMF2-score demonstrated that patients with higher TCMF2-score exhibited worse 5-year DFS in three cohorts. P values were calculated using the log-rank test. f ROC analysis of the sensitivity and specificity of the 5-year DFS for the TCMF2-score in three cohorts.
